Human papillomavirus (9-valent) vaccine is under clinical development by Xiamen Innovax Biotech and currently in Phase II for Human Papillomavirus Infections.

Goflikicept is under clinical development by R-Pharm and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

MIB-626 is under clinical development by Metro International Biotech and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Immunological Disorders.

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).

Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 30% phase transition success rate (PTSR) ...

Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Inflammatory Bowel Disease.